Natali 1985.

Methods	Study design: double blind randomised clinical trial. Method of randomisation: not stated.
Participants	Country: France. Setting: outpatient setting. Number randomised: 18, treatment group 9, control group 9. Age: treatment group 60.8, control group 66.2. Sex: treatment group 7 males and 2 females, control group 8 males and 1 female. Inclusion criteria: Patients with PAD (stage IIb according to Fontaine); age 30 to 75 years; occlusive lesions of deep femoral arteries verified by arteriography; stable condition. Exclusion criteria: non co‐operative patient; significant psychiatric disorder; physical condition that does not allow exercise tests to be performed; any other ailment that could influence the course of the PAD or interfere with the assessment of treatment effects (e.g. Parkinson's disease, tumours); treatment of the same type as the product studied; treatment that could interfere with the assessment of treatment effects.
Interventions	Treatment: 160 mg Ginkgo biloba special extract EgB 761 daily. Control: placebo. Duration: 6 months.
Outcomes	Walking distance: ACD and ICD by treadmill testing (3 km/h and 5% incline); adverse reactions.
Notes	Conflicts of interests: Internal rapport of Dr. Wilmar Schwabe Arzneimittel/Pharmaceuticals, Karlsruhe, Germany
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Patients were randomised.
Allocation concealment (selection bias)	Unclear risk	Insufficient information.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	The intervention and the placebo were presented the same way.